PYPD

PolyPid Ltd. [PYPD] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

PYPD Stock Summary

In the News

07:00 29 Mar 2024 PYPD

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.

01:00 29 Mar 2024 PYPD

PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?

PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

11:13 29 Mar 2024 PYPD

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

07:00 29 Mar 2024 PYPD

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

01:08 29 Mar 2024 PYPD

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript

PolyPid Ltd. (NASDAQ:PYPD ) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET Company Participants Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Raghuram Selvaraju - H.C.

07:00 29 Mar 2024 PYPD

PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

PETACH TIKVA, Israel, Sept. 22, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company's management will present at the Cantor Global Healthcare Conference taking place on September 26-28, 2023, in New York City, New York.

12:55 29 Mar 2024 PYPD

PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript

PolyPid Ltd (NASDAQ:PYPD ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO & Director Jonny Missulawin - CFO Ori Warshavsky - COO Conference Call Participants Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Second Quarter 2023 Conference Call. [Operator Instructions].

07:00 29 Mar 2024 PYPD

PolyPid to Participate in Upcoming Investor Conferences

PETACH TIKVA, Israel, April 24, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that members of management will participate in the following upcoming investor conferences:

01:20 29 Mar 2024 PYPD

PolyPid Ltd (PYPD) Q4 2022 Earnings Call Transcript

PolyPid Ltd (NASDAQ:PYPD ) Q4 2022 Earnings Conference Call February 8, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO Ori Warshavsky - COO, US Jonny Missulawin - SVP, Finance Conference Call Participants Brandon Folkes - Cantor Fitzgerald Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Fourth Quarter and Full Year 2022 Conference Call. [Operator Instructions].

07:00 29 Mar 2024 PYPD

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full year 2022 financial results and operational highlights before the open of the U.S. stock markets on Wednesday, February 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PYPD Financial details

Company Rating
Sell
Market Cap
7.77M
Income
-23.87M
Revenue
0
Book val./share
-1.27
Cash/share
3.39
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.47
Forward P/E
-1.94
PEG
0.07
P/S
-
P/B
3.21
P/C
1.36
P/FCF
-0.36
Quick Ratio
1.72
Current Ratio
1.89
Debt / Equity
-5.21
LT Debt / Equity
-3.04
-
-
EPS (TTM)
-19.66
EPS next Y
-2.37
EPS next Q
-1.58
EPS this Y
-69.2%
EPS next Y
-87.95%
EPS next 5Y
-257.17%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
12.94%
-
-
-
-
SMA20
-13.79%
SMA50
-28.09%
SMA100
27.65%
Inst Own
1.8%
Inst Trans
1.3%
ROA
-115%
ROE
-330%
ROC
-0.79%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
1.65M
Shs Float
886.01K
-
-
-
-
Target Price
-
52W Range
3.566-14.7
52W High
-67.14%
52W Low
+53.33%
RSI
39.55
Rel Volume
0.62
Avg Volume
7.38K
Volume
4.57K
Perf Week
-12.88%
Perf Month
-32.75%
Perf Quarter
7.73%
Perf Half Y
-13.21%
-
-
-
-
Beta
1.43
-
-
Volatility
0.24%, 0.52%
Prev Close
-2.13%
Price
4.6
Change
-2.13%

PYPD Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
10.72-57.3-65.24-55.16-16.99
Operating cash flow per share
-39.16-35.03-51.9-47.89-12.27
Free cash flow per share
-41.15-36.94-56.69-50.36-12.41
Cash per share
60.0772.1451.617.583.99
Book value per share
69.8118.0558.068.18-1.49
Tangible book value per share
69.8118.0558.068.18-1.49
Share holders equity per share
69.8118.0558.068.18-1.49
Interest debt per share
0.030.03020.599
Market cap
252.63M183.1M107.46M15M5.34M
Enterprise value
248.7M178.78M97.64M20.18M11.51M
P/E ratio
53.19-5.18-2.64-0.38-0.22
Price to sales ratio
00000
POCF ratio
-14.55-8.48-3.32-0.44-0.31
PFCF ratio
-13.85-8.04-3.04-0.42-0.31
P/B Ratio
8.172.522.972.56-2.55
PTB ratio
8.172.522.972.56-2.55
EV to sales
00000
Enterprise value over EBITDA
-8.51-6.8-2.28-0.52-0.55
EV to operating cash flow
-14.33-8.28-3.01-0.59-0.67
EV to free cash flow
-13.64-7.85-2.76-0.56-0.66
Earnings yield
0.02-0.19-0.38-2.63-4.47
Free cash flow yield
-0.07-0.12-0.33-2.4-3.27
Debt to equity
0002.34-5.21
Debt to assets
0000.530.71
Net debt to EBITDA
0.130.160.23-0.13-0.29
Current ratio
10.6316.544.461.640.83
Interest coverage
-1.24K-1.55K0-38.01-13.36
Income quality
2.510.590.760.870.72
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.050.050.090.050.01
Capex to revenue
00000
Capex to depreciation
-0.93-1.16-2.68-1.03-0.11
Stock based compensation to revenue
00000
Graham number
129.73390.12291.93100.7523.89
ROIC
0.41-0.35-1.14-1.79-2.37
Return on tangible assets
0.14-0.47-0.92-1.52-1.55
Graham Net
54.1567.8620.89-10.03-8.44
Working capital
24.84M44.72M27.01M5.55M-1.22M
Tangible asset value
30.94M72.78M36.23M5.86M-2.1M
Net current asset value
24.58M44.53M26.81M-5.92M-11.4M
Invested capital
0002.34-5.21
Average receivables
21K90.5K128.5K208K149K
Average payables
1.36M1.28M2.56M2.64M956.5K
Average inventory
175.5K498.5K-10.93M-11.14M106.5K
Days sales outstanding
00000
Days payables outstanding
609.36351.291.35K241.99154.65
Days of inventory on hand
135.29232.99-7.35K45.170
Receivables turnover
00000
Payables turnover
0.61.040.271.512.36
Inventory turnover
2.71.57-0.058.080
ROE
0.15-0.49-1.12-6.7411.39
Capex per share
-1.98-1.91-4.8-2.47-0.14

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-9.97-8.47-3.95-3.4-3.84
Operating cash flow per share
-48.160000
Free cash flow per share
-47.940000
Cash per share
19.2218.7410.216.153.39
Book value per share
8.9415.925.642.14-1.27
Tangible book value per share
8.9415.925.642.14-1.27
Share holders equity per share
8.9415.925.642.14-1.27
Interest debt per share
21.1134.438.247.376.82
Market cap
13.72M9.89M16.2M7.44M6.28M
Enterprise value
18.9M16.36M24.98M17.93M12.45M
P/E ratio
-0.52-0.41-0.69-0.33-0.25
Price to sales ratio
00000
POCF ratio
-0.430000
PFCF ratio
-0.440000
P/B Ratio
2.340.871.942.1-3
PTB ratio
2.340.871.942.1-3
EV to sales
00000
Enterprise value over EBITDA
-2.86-2.83-4.29-3.41-2.08
EV to operating cash flow
-0.60000
EV to free cash flow
-0.60000
Earnings yield
-0.48-0.61-0.36-0.75-1.01
Free cash flow yield
-2.290000
Debt to equity
2.341.131.463.35-5.21
Debt to assets
0.530.410.460.570.71
Net debt to EBITDA
-0.78-1.12-1.51-1.99-1.03
Current ratio
1.642.752.891.890.83
Interest coverage
-66.120.49-831.43-16.49-17.24
Income quality
4.830000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
-0.550000
Stock based compensation to revenue
00000
Graham number
44.855.0722.3812.810.47
ROIC
-0.310.22-0.26-0.32-0.62
Return on tangible assets
-0.25-0.19-0.22-0.27-0.41
Graham Net
-10.97-2.73-1.9-4.39-7.17
Working capital
5.55M13.09M10.3M5.22M-1.22M
Tangible asset value
5.86M11.41M8.35M3.54M-2.1M
Net current asset value
-5.92M297K-2.16M-6.27M-11.4M
Invested capital
2.341.131.463.35-5.21
Average receivables
149K3.25M3.1M00
Average payables
1.09M1.11M993K716K650.5K
Average inventory
106.5K358.5K252K00
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.11-0.53-0.7-1.583.03
Capex per share
0.210000

PYPD Frequently Asked Questions

What is PolyPid Ltd. stock symbol ?

PolyPid Ltd. is a IL stock and trading under the symbol PYPD

What is PolyPid Ltd. stock quote today ?

PolyPid Ltd. stock price is $4.6 today.

Is PolyPid Ltd. stock public?

Yes, PolyPid Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap